Gemini Stock Analysis

GMTX -  USA Stock  

USD 10.81  0.20  1.89%

The big decline in price over the last few months for Gemini Therapeuticsmay raise some interest from investors. The stock closed today at a share price of 10.81 on 5,550 in trading volume. The company management teams failed to add value to investors and positioning the firm supply of money to exploit market volatility in May. However, diversifying your holdings with Gemini Therapeutics or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.47. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Gemini Therapeutics partners.
Please check Risk vs Return Analysis.

Search Stock Analysis 

The Gemini Therapeutics stock analysis report makes it easy to digest most publicly released information about Gemini Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Gemini stock analysis module also helps to analyze the Gemini Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Gemini Stock Analysis Notes

The company had not issued any dividends in recent years. Gemini Therapeutics, Inc., a precision medicine company, focuses on the development of new therapies for patients suffering from dry AMD and linked diseases. The company was founded in 2015 and is based in Cambridge, Massachusetts. Gemini Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. To learn more about Gemini Therapeutics call the company at 617 678 3113 or check out

Gemini Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Gemini Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Gemini Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Gemini Therapeutics generates negative expected return over the last 90 days
Gemini Therapeutics has high historical volatility and very poor performance
Gemini Therapeutics has high likelihood to experience some financial distress in the next 2 years
Gemini Therapeutics was previously known as Gemini Therapeutics and was traded on NASDAQ Exchange under the symbol FSDC.
Gemini Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from Gemini Therapeutics Inc gains 4.1840 percent for June 10 -

Gemini Largest EPS Surprises

Earnings surprises can significantly impact Gemini Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Gemini Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Gemini Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Gemini Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Gemini Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
13th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
7th of May 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
14th of April 2021
Financial Statements and Exhibits. Other Events. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
29th of March 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
23rd of February 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
22nd of February 2021
Unclassified Corporate Event
16th of February 2021
Unclassified Corporate Event. Unclassified Corporate Event
12th of February 2021
Unclassified Corporate Event. Unclassified Corporate Event

Gemini Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Gemini Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Gemini Therapeutics backward and forwards among themselves. Gemini Therapeutics' institutional investor refers to the entity that pools money to purchase Gemini Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Orbimed Advisors LlcCommon Shares5.8 M78.9 M
Fmr LlcCommon Shares2.8 M36.1 M
Foresite Capital Management V LlcCommon Shares2.4 M33 M
Vanguard Group IncCommon Shares1.8 M25 M
Wellington Management Group LlpCommon Shares1.5 M19.7 M
Suvretta Capital Management LlcCommon Shares1.3 M17.8 M
Boxer Capital LlcCommon Shares1.3 M17.6 M
Caption Management LlcCall Options365.5 KM
Note, although Gemini Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Gemini Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 574.88 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Gemini Therapeutics's market, we take the total number of its shares issued and multiply it by Gemini Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Gemini Profitablity

Gemini Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Gemini Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Gemini Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Gemini Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Gemini Therapeutics' profitability requires more research than a typical breakdown of Gemini Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(5.08) (5.48) 
Return on Average Equity 0.79  0.78 
Return on Invested Capital(15.24) (16.44) 

Management Efficiency

Return on Average Assets is likely to drop to -5.48 in 2021. Return on Average Equity is likely to drop to 0.78 in 2021. Gemini Therapeutics Total Assets are fairly stable at the moment as compared to the past year. Gemini Therapeutics reported Total Assets of 8.32 Million in 2020. Tangible Assets Book Value per Share is likely to rise to 1.54 in 2021, whereas Current Assets are likely to drop slightly above 4.8 M in 2021. Gemini Therapeutics management efficiency ratios could be used to measure how well gemini therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Last ReportedProjected for 2021
Book Value per Share(3.85) (4.15) 
Enterprise Value over EBIT(0.90) (0.97) 
Enterprise Value over EBITDA(1.30) (1.41) 
Price to Book Value(7.04) (7.59) 
Tangible Assets Book Value per Share 1.47  1.54 
Enterprise Value43.8 M43.6 M
Tangible Asset Value8.3 M8.6 M

Technical Drivers

As of the 17th of June 2021, Gemini Therapeutics retains the market risk adjusted performance of (0.27), and Risk Adjusted Performance of (0.07). Gemini Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Gemini Therapeutics, which can be compared to its competitors. Please check out Gemini Therapeutics coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Gemini Therapeutics is priced fairly, providing market reflects its last-minute price of 10.81 per share. Given that Gemini Therapeutics has jensen alpha of (0.78), we strongly advise you to confirm Gemini Therapeutics's regular market performance to make sure the company can sustain itself at a future point.

Gemini Therapeutics Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Exponential Moving Average is calculated by weighting recent values of Gemini Therapeutics more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Gemini Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gemini Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gemini Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Gemini Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Gemini Therapeutics Predictive Daily Indicators

Gemini Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Gemini Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Gemini Therapeutics Forecast Models

Gemini Therapeutics time-series forecasting models is one of many Gemini Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Gemini Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Gemini Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Gemini Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Gemini shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Gemini Therapeutics. By using and applying Gemini Stock analysis, traders can create a robust methodology for identifying Gemini entry and exit points for their positions.
Gemini Therapeutics, Inc., a precision medicine company, focuses on the development of new therapies for patients suffering from dry AMD and linked diseases. The company was founded in 2015 and is based in Cambridge, Massachusetts. Gemini Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.

Current Gemini Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Gemini analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Gemini analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
22.67Strong Buy3Odds
Gemini Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Gemini analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Gemini stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Gemini Therapeutics, talking to its executives and customers, or listening to Gemini conference calls.
Gemini Analyst Advice Details

Gemini Stock Analysis Indicators

Gemini Therapeutics stock analysis indicators help investors evaluate how Gemini Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Gemini Therapeutics shares will generate the highest return on investment. By understating and applying Gemini Therapeutics stock analysis, traders can identify Gemini Therapeutics position entry and exit signals to maximize returns.
Fifty Two Week Low11.06
Fifty Two Week High13.50
Average Daily Volume Last 10 Day193.1k
Average Daily Volume In Three Month193.1k
Fifty Day Average12.59
Two Hundred Day Average12.59
Please check Risk vs Return Analysis. Note that the Gemini Therapeutics information on this page should be used as a complementary analysis to other Gemini Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Gemini Therapeutics Stock analysis

When running Gemini Therapeutics stock analysis, check to measure Gemini Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gemini Therapeutics is operating at the current time. Most of Gemini Therapeutics' stock examination focuses on studying past and present price action to predict the probability of Gemini Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Gemini Therapeutics' price. Additionally, you may evaluate how the addition of Gemini Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
The market value of Gemini Therapeutics is measured differently than its book value, which is the value of Gemini that is recorded on the company's balance sheet. Investors also form their own opinion of Gemini Therapeutics stock's value that differs from its market value or its book value, called intrinsic value, which is Gemini Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gemini Therapeutics' market value can be influenced by many factors that don't directly affect Gemini Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gemini Therapeutics' stock value and its price as these two are different measures arrived at by different means. Investors typically determine Gemini Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gemini Therapeutics' stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.